JP6896636B2 - 組換えタンパク質薬の分子設計 - Google Patents

組換えタンパク質薬の分子設計 Download PDF

Info

Publication number
JP6896636B2
JP6896636B2 JP2017542389A JP2017542389A JP6896636B2 JP 6896636 B2 JP6896636 B2 JP 6896636B2 JP 2017542389 A JP2017542389 A JP 2017542389A JP 2017542389 A JP2017542389 A JP 2017542389A JP 6896636 B2 JP6896636 B2 JP 6896636B2
Authority
JP
Japan
Prior art keywords
seq
mutant
motif
amino acid
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017542389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018507854A (ja
JP2018507854A5 (enExample
Inventor
ヨンチャン、ルオ
ペン、リウ
シンアン、ルー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Publication of JP2018507854A publication Critical patent/JP2018507854A/ja
Publication of JP2018507854A5 publication Critical patent/JP2018507854A5/ja
Application granted granted Critical
Publication of JP6896636B2 publication Critical patent/JP6896636B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017542389A 2015-02-13 2016-02-14 組換えタンパク質薬の分子設計 Active JP6896636B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201510079486 2015-02-13
CN201510079486.7 2015-02-13
CN201510736184 2015-11-02
CN201510736184.2 2015-11-02
PCT/CN2016/073773 WO2016127948A1 (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计

Publications (3)

Publication Number Publication Date
JP2018507854A JP2018507854A (ja) 2018-03-22
JP2018507854A5 JP2018507854A5 (enExample) 2019-03-14
JP6896636B2 true JP6896636B2 (ja) 2021-06-30

Family

ID=56614147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017542389A Active JP6896636B2 (ja) 2015-02-13 2016-02-14 組換えタンパク質薬の分子設計

Country Status (8)

Country Link
US (2) US10869910B2 (enExample)
EP (1) EP3269731B1 (enExample)
JP (1) JP6896636B2 (enExample)
CN (2) CN114249816B (enExample)
AU (2) AU2016218635B2 (enExample)
CA (1) CA3014538A1 (enExample)
DK (1) DK3269731T5 (enExample)
WO (1) WO2016127948A1 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101890155B (zh) * 2010-05-25 2012-07-25 江苏先声药物研究有限公司 一种药物组合物及其应用
WO2013034116A1 (zh) * 2011-09-09 2013-03-14 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体
CN107148277B (zh) * 2014-11-03 2022-03-22 清华大学 一种抑制脂肪细胞分化和胰岛素耐受的药物

Also Published As

Publication number Publication date
EP3269731A4 (en) 2018-08-15
EP3269731B1 (en) 2023-10-04
AU2020256316A1 (en) 2020-11-12
CA3014538A1 (en) 2016-08-18
AU2016218635A1 (en) 2017-10-05
CN114249816A (zh) 2022-03-29
CN114249816B (zh) 2024-09-06
CN107428809A (zh) 2017-12-01
WO2016127948A1 (zh) 2016-08-18
US20180200337A1 (en) 2018-07-19
US20210085754A1 (en) 2021-03-25
JP2018507854A (ja) 2018-03-22
AU2016218635B2 (en) 2020-07-23
DK3269731T5 (da) 2024-10-14
AU2020256316B2 (en) 2021-10-07
US10869910B2 (en) 2020-12-22
DK3269731T3 (da) 2023-10-30
EP3269731A1 (en) 2018-01-17
CN107428809B (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
JP6243452B2 (ja) アルブミン結合アルギニンデイミナーゼ融合たんぱく質を含有する医薬組成物
Terzyan et al. The three-dimensional structure of human RNase 4, unliganded and complexed with d (Up), reveals the basis for its uridine selectivity
CN1699408A (zh) 高效抑制血管生成多肽及其制备方法和应用
JP7729842B2 (ja) ｒｈＦＧＦ２１融合タンパク質、ｒｈＦＧＦ２１融合タンパク質をコードするポリヌクレオチド、ｒｈＦＧＦ２１融合タンパク質を含有する組成物、及びｒｈＦＧＦ２１融合タンパク質の使用
US20180163214A1 (en) Slit2d2-hsa fusion protein and use thereof against tumours
JP2003509042A (ja) 新規血管形成阻害剤
CN103897038A (zh) 一种肿瘤抑制多肽及用途
CN112851791B (zh) 一种新型抗代谢紊乱的fgf类似物及其应用
AU2020256316B2 (en) Molecular design of recombinant protein drug
CN117157308A (zh) 细胞穿膜肽变体及其用途
CN106432483B (zh) 沼水蛙皮肤丝氨酸蛋白酶抑制肽及其基因和制药应用
CN103755813B (zh) 一种靶向性抗肿瘤融合蛋白及其编码基因与表达质粒
CN102260352B (zh) 靶向性白细胞介素融合蛋白及其制备方法与应用
RU2285537C1 (ru) Противоопухолевый пептидный препарат на основе фрагмента альфа-фетопротеина, его конъюгат, фармацевтическая композиция и способ лечения гормонзависимых опухолей
KR101651330B1 (ko) 세포투과성이 우수한 ｔａｔ－ａ２０ 융합단백질의 제조방법 및 이의 용도
HK1240943B (zh) 一种重组蛋白质药物的分子设计
HK1240943A1 (en) Molecular design of recombinant protein drug
WO2021205150A1 (en) An enzyme
CN101356190A (zh) 用于抑制pf4和rantes相互作用的拮抗剂
WO2004091650A1 (fr) Utilisation de la troponine i cardiaque pour preparer des medicaments antitumoraux
CN120192429B (zh) 一种dhodh多肽降解剂及其在制备预防和/或治疗dhodh介导的疾病的药物中的应用
CN100487118C (zh) 一种重组人角质细胞生长因子-2的生产方法
CN117384269A (zh) 短肽mfrlp及其在制备动脉重塑相关疾病药物中的应用
WO2010095422A1 (ja) 悪性腫瘍治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210301

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210511

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210609

R150 Certificate of patent or registration of utility model

Ref document number: 6896636

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250